Log in to save to my catalogue

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in...

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_055f322f354a4bb88572f00b0542def1

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer

About this item

Full title

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer

Publisher

Melbourne: John Wiley & Sons Australia, Ltd

Journal title

Thoracic cancer, 2022-07, Vol.13 (14), p.2064-2074

Language

English

Formats

Publication information

Publisher

Melbourne: John Wiley & Sons Australia, Ltd

More information

Scope and Contents

Contents

Background
Cancer cachexia and tumor burden predict efficacies of programmed cell death‐1 (PD‐1)/programmed death‐ligand 1 (PD‐L1) inhibitors and chemotherapy or pembrolizumab in non‐small cell lung cancer (NSCLC). There are no predictive models that simultaneously assess cancer cachexia and tumor burden.
Methods
In the present retrospecti...

Alternative Titles

Full title

Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_055f322f354a4bb88572f00b0542def1

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_055f322f354a4bb88572f00b0542def1

Other Identifiers

ISSN

1759-7706

E-ISSN

1759-7714

DOI

10.1111/1759-7714.14529

How to access this item